Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death

Journal of Inorganic Biochemistry

Volumn 101, Issue 4, 2007, Pages 551-558

  González Vadillo, Ana M ^a   Álvarez Valdés, Amparo ^a   Moneo, Victoria ^b   Blanco, Fernando ^b   Díaz, Raquel G ^b,c   Carnero, Amancio ^b   Navarro Ranninger, Carmen ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Antitumor drugs; Cell cycle; Cytotoxic activity; Platinum anticancer drugs; Transplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOHEXYLAMINE DIMETHYLAMINE PLATINUM CHLORIDE; DIMETHYLAMINE PROPYLAMINE PLATINUM CHLORIDE; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CYCLOHEXYLAMINES; HUMANS; ORGANOPLATINUM COMPOUNDS; PLATINUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847383358     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinorgbio.2006.11.015     Document Type: Article

References (55)

1. Rosenberg B., van Camp L., and Krigas T. Nature 205 (1965) 698-699
2. Hambley T.W. Coord. Chem. Rev. 166 (1997) 181-223
3. Hall M.D., and Hambley T.W. Coord. Chem. Rev. 232 (2002) 49-67
4. Zhang C.X., and Lippard S.J. Curr. Opin. Chem. Biol. 7 (2003) 481-489
5. Reedijk J. Proc. Natl. Acad. Sci. USA 100 (2003) 3611-3616
6. Cleare M.J., and Hoeschele J.D. Plat. Met. Rev. 17 (1973) 2-13
7. Cohen S.M., and Lippard S.J. Prog. Nucleic Acid Res. Mol. Biol. 67 (2001) 93-130
8. Brabec V. Prog. Nucleic Acid Res. Mol. Biol. 71 (2002) 1-68
9. Kelland L.R. Drugs 59 (2000) 1-8
10. Brabec V., and Kasparkova J. Drug Resist. Updates 5 (2002) 147-161
11. Farrell N. Cancer Invest. 11 (1993) 578-589
12. Zdraveski Z.Z., Mello J.A., Farinelli C.K., Essigmann J.M., and Marinus M.G. J. Biol. Chem. 277 (2002) 1255-1260
13. Teixeira L.J., Seabra M., Reis E., Girao da Cruz M.T., Conceiçao Pedroso da Lima M., Pereira E., Miranda M.A., and Marques M.P.M. J. Med. Chem. 47 (2004) 2917-2925
14. Farrell N., Kelland L.R., Roberts J.D., and Van Beusichem M. Cancer Res. 52 (1992) 5065-5072
15. Farrell N. Current Status of Structure-activity Relationships of Platinum Anticancer Drugs: Activation of trans Geometry. Metal Ions in Biological Systems vol. 32 (1996), Marcel Dekker, New York p. 603
16. Kelland L.R., Barnard C.F.J., Mellish K.J., Jones M., Goddard P.M., Valenti M., Bryant A., Murrer B.A., and Harrap K.R. Cancer Res. 54 (1994) 5618-5622
17. Pérez J.M., Montero E.I., González A.M., Solans X., Font-Bardia M., Fuertes M.A., Alonso C., and Navarro-Ranninger C. J. Med. Chem. 43 (2000) 2411-2418
18. Coluccia M., Nassi A., Loseto F., Boccarelli A., Mariggio M.A., Giordano D., Intini F.P., Caputo P.A., and Natile G. J. Med. Chem. 36 (1993) 510-512
19. Natile G., and Coluccia M. Coord. Chem. Rev. 216-217 (2001) 383-410
20. Pérez J.M., Fuertes M.A., Alonso C., and Navarro-Ranninger C. Crit. Rev. Oncol. Hematol. 35 (2000) 109-120
21. Leng M., Locker D., Giraud-Panis M.J., Schwartz A., Intini F.P., Natile G., Pisano C., Boccarelli A., Giordano D., and Coluccia M. Mol. Pharmacol. 58 (2000) 1525-1535
22. Pantoja E., Álvarez-Valdés A., Pérez J.M., Navarro-Ranninger C., and Reedijk J. Inorg. Chim. Acta 339 (2002) 525-531
23. Pérez J.M., Kelland L.R., Montero E.I., Boxal F.E., Fuertes M.A., Alonso C., and Navarro-Ranninger C. Mol. Pharmacol. 63 (2003) 933-944
24. Prokop R., Kasparkova J., Novakova O., Marini V., Pizarro A.M., Navarro-Ranninger C., and Brabec V. Biochem. Pharmacol. 67 (2004) 1097-1109
25. Najajreh Y., Perez J.M., Navarro-Ranninger C., and Gibson D. J. Med. Chem. 45 (2002) 5189-5195
26. Barnard C.F.J., Raynaud F.I., and Kelland L.R. In: Clarke M.J., and Sadler P.J. (Eds). Metallopharmaceuticals I DNA Interactions (1999), Springer, Berlin 45
27. Kelland L.R., Abel G., McKeage M.J., Jones M., Goddard P.M., Valenti M., Murrer B.A., and Harrap K.R. Cancer Res. 53 (1993) 2581-2586
28. Wyllie A.H. Br. J. Cancer 67 (1993) 205-208
29. Wyllie A.H., Kerr J.F.R., and Currie A.R. Int. Rev. Cytol. 68 (1980) 251-305
30. O'Neill C.F., Ormerod M.G., Robertson D., Titley J.C., Cumber-Walsweer Y., and Kelland L.R. Br. J. Cancer 74 (1996) 1037-1045
31. Montero E.I., Díaz S., González-Vadillo A.M., Pérez J.M., Alonso C., and Navarro-Ranninger C. J. Med. Chem. 42 (1999) 4264-4268
32. Talman E.G., Brüning W., Reedijk J., Spek A.L., and Veldman N. Inorg. Chem. 36 (1997) 854-861
33. Kelland L.R., Barnard C.F.J., Evans I.G., Murrer B.A., Theobald B.R.C., Wyer S.B., Goddard P.M., Jones M., Valenti M., Bryant A., Rogers P.M., and Harrap K.R. J. Med. Chem. 38 (1995) 3016-3024
34. Pérez J.M., Camazón M., Álvarez-Valdés A., Quiroga A.G., Kelland L.R., Alonso C., and Navarro-Ranninger C. Chem. Biol. Interact. 117 (1999) 99-115
35. Bax A.D., and Morris G.A. J. Magn. Reson. 42 (1981) 501-505
36. Nakamoto K. Infrared and Raman Spectra of Inorganic and Coordination Compounds. fifth ed. (1997), Willey, New York 346
37. Ferraro J.R. Low-Frequency Vibrations of Inorganic and Coordination Compounds (1971), Plenum, New York 165
38. Giandomenico C.M., Abrams M.J., Murrer B.A., Vollano J.D., Rheinheimer M.I., Wyer S.B., Bossard G.E., and Higgins J.D. Inorg. Chem. 34 (1995) 1015-1021
39. Kuroda R., Neidle S., Ismail I.M., and Sadler P.J. Inorg. Chem. 22 (1983) 3620-3624
40. Pregosin P.S. Coord. Chem. Rev. 44 (1982) 247-291
41. Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., and Harrap K.R. Br. J. Cancer 59 (1989) 527-534
42. Umapathy P. Coord. Chem. Rev. 95 (1989) 129-181
43. Pors K., Paniwnyk Z., Ruparelia K.C., Teesdale-Spittle P.H., Hartley J.A., Kelland L.R., and Patterson L.H. J. Med. Chem. 47 (2004) 1856-1859
44. Demarcq C., Bastian G., and Remvikos Y. Cytometry 13 (1992) 416-422
45. Coluccia M., Nassi A., Boccarelli A., Giordano D., Cardellicchio N., Locker D., Leng M., Sivo M., Intini F.P., and Natile G. J. Inorg. Biochem. 77 (1999) 31-35
46. Coluccia M., Nassi A., Boccarelli A., Giordano D., Cardellicchio N., Intini F.P., Natile G., Barletta A., and Paradiso A. Int. J. Oncol. 15 (1999) 1039-1044
47. Ormerod M., O'Neill C., Roberstson D., Kelland L.R., and Harrap K.R. Cancer Chemother. Pharmacol. 37 (1996) 463-471
48. Orlandi L., Colella A., Bearzatto A., Abolafio G., Manzotti C., Daidone M.G., and Zaffaroni N. Eur. J. Cancer 37 (2001) 649-659
49. Pinto A.L., and Lippard S.J. Biochim. Biophys. Acta 780 (1985) 167-180
50. O'Connor P.M., and Fan S. Cell Cycle Res. 2 (1996) 165-173
51. Pucci B., Kasten M., and Giordano A. Neoplasia 2 (2000) 291-299
52. Nguyen H.N., Sevin B., Averette H.E., Perras J., Ramos R., Angioli R., and Ochiai K. Int. J. Oncol. 3 (1993) 375-382
53. Ormerod M.G., Orr R.M., and Peacock J.H. Br. J. Cancer 69 (1994) 93-100
54. Eliopoulos A.G., Kerr D.J., Herod J., Hodgkins L., Krajewski S., Reed J.C., and Young L.S. Oncogene 11 (1995) 1217-1228
55. Hagopian G.S., Mills G.B., Khokhar A.R., Bast Jr. R.C., and Siddik Z.H. Clin. Cancer Res. 5 (1999) 655-663